How the Medical-Industrial Complex Overwrote Evidence-Based Medicine—And Why Fiduciaries Must Push Back

In our previous post, we detailed the remarkable economic pivot of the mid-2000s: Big Pharma quietly abandoned basic cardiovascular and metabolic drug development because first-generation “wonder drugs”—metformin, statins, ACE inhibitors, ARBs, eplerenone, and aspirin—set a clinical and economic bar that new, expensive single-molecule drugs simply could not beat.